慢性鼻窦炎手术治疗临床实践指南执行摘要
本指南由美国耳鼻咽喉头颈外科学会制定,针对成人慢性鼻窦炎的手术治疗提出关键行动声明。指南强调术前应核实诊断、评估手术适应证,不推荐无脓性分泌物时使用抗菌药物,并反对将固定疗程的药物治疗作为手术前提。指南还就患者咨询、CT扫描、手术范围、术后随访等提出推荐,其中部分为强推荐,部分为推荐。
要点
- 术前应核实慢性鼻窦炎诊断并依据症状、疾病特征、生活质量和既往治疗评估手术适应证(强推荐)。
- 无显著或持续脓性鼻漏时,不应处方抗菌治疗(强推荐)。
- 不推荐将固定统一的药物治疗方案或疗程作为手术前提(推荐)。
核心结论
- 指南为成人慢性鼻窦炎的手术管理提供循证推荐,旨在识别质量改进机会。
- 指南发展组对术前诊断核实、手术适应证评估和无脓性分泌物时避免抗菌治疗作出强推荐。
- 对其他若干关键行动声明作出推荐,无选项级推荐。
研究设计与样本
- 指南采用美国耳鼻咽喉头颈外科学会临床实践指南发展手册(第3版)的55页方案制定。
- 指南发展组代表耳鼻咽喉科医生、鼻科医生、高级实践护士和医师助理以及消费者。
- 目标受众为管理成人慢性鼻窦炎的耳鼻咽喉头颈外科医生。
主要发现
- 强推荐:术前应核实慢性鼻窦炎诊断以确保符合临床实践指南的诊断标准(体征和症状),并基于症状、疾病特征、生活质量和既往药物或手术治疗评估手术适应证(KAS 1A和1B)。
- 强推荐:若无显著或持续脓性鼻漏(前、后或两者),不应处方抗菌治疗(KAS 3)。
- 推荐:不应将预先设定的、一刀切的药物治疗方案或疗程(如抗生素、类固醇、抗组胺药)作为手术前提(KAS 2)。
- 推荐:应识别最可能从手术获益且最不可能从继续单独药物治疗获益的患者,如伴鼻息肉、息肉伴骨侵蚀、嗜酸性黏蛋白或真菌球的亚型(KAS 4)。
- 推荐:术前应咨询患者建立现实期望,包括慢性化或复发可能及长期药物管理的可能性(KAS 5)。
关键数值与推荐
- 强推荐(KAS 1A):术前核实慢性鼻窦炎诊断,确保符合临床实践指南的诊断标准(体征和症状)。
- 强推荐(KAS 1B):基于症状、疾病特征、生活质量和既往药物或手术治疗评估手术适应证。
- 强推荐(KAS 3):无显著或持续脓性鼻漏(前、后或两者)时,不应处方抗菌治疗。
- 推荐(KAS 2):不应将预先设定的、一刀切的药物治疗方案或疗程作为手术前提。
- 推荐(KAS 4):识别最可能从手术获益且最不可能从继续单独药物治疗获益的患者,如伴鼻息肉、息肉伴骨侵蚀、嗜酸性黏蛋白或真菌球的亚型。
临床怎么用
- 术前应核实诊断并评估手术适应证,无脓性鼻漏时不应处方抗菌治疗(强推荐)。
- 不应要求固定统一的药物治疗方案或疗程作为手术前提(推荐)。
- 应识别最可能从手术获益的患者亚型,如伴鼻息肉、息肉伴骨侵蚀、嗜酸性黏蛋白或真菌球(推荐)。
- 术前应咨询患者建立现实期望,包括慢性化或复发可能及长期药物管理(推荐)。
- 预计获益超过单独非手术治疗、结局明确且患者理解术后长期管理期望时,应提供手术(推荐)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The purpose of this specialty-specific clinical practice guideline is to identify quality improvement opportunities and provide clinicians with trustworthy, evidence-based recommendations for the surgical management of chronic rhinosinusitis in adults. The target audience includes otolaryngologist-head and neck surgeons who manage adults with chronic rhinosinusitis, including candidacy and performance of endoscopic sinus surgery. METHODS: This executive summary describes the guideline developed using the 55-page protocol published as the American Academy of Otolaryngology-Head and Neck Surgery Foundation's Clinical Practice Guideline Development Manual (3rd edition), which summarizes the methodology for assessments of current data, topic prioritization, development of key action statements (KASs), application of value judgments, and related procedures. The guideline group represented otolaryngologists, rhinologists, advanced practice nursing and physician assistants, and consumers who represented participating national professional organizations. ACTION STATEMENTS: The Guideline Development Group made strong recommendations for the following KASs: Before considering surgery, the surgeon should verify an existing diagnosis of chronic rhinosinusitis to ensure established diagnostic criteria (signs and symptoms) from clinical practice guidelines are met, and the surgeon should assess candidacy for sinus surgery based on symptoms, disease characteristics, quality of life, and prior medical or surgical therapy (KASs 1A and 1B). The surgeon or their designee should not prescribe antibacterial therapy to an adult with chronic rhinosinusitis if significant or persistent purulent nasal discharge (anterior, posterior, or both) is absent on examination (KAS 3). The Guideline Development Group made recommendations for the following KASs: The surgeon should not endorse or require a predefined, one-size-fits-all regimen or duration of medical therapy (eg, antibiotics, steroids, antihistamines) as a prerequisite to sinus surgery for an adult with chronic rhinosinusitis (KAS 2). The surgeon should identify patients with chronic rhinosinusitis that would benefit most from surgery and are least likely to benefit from continued medical therapy alone, such as those with chronic rhinosinusitis subtypes that include, but are not limited to, chronic rhinosinusitis with polyps, polyps with bony erosion, eosinophilic mucin, or fungal balls (KAS 4). The surgeon or their designee should counsel patients before sinus surgery to establish realistic expectations, including the potential for chronicity or relapse, and the likelihood of long-term medical management, taking into account their chronic rhinosinusitis subtype (KAS 5). The surgeon should offer sinus surgery to an adult with chronic rhinosinusitis when the anticipated benefits exceed that of nonsurgical management alone, there is clarity regarding the anticipated outcomes, and the patient understands the expectation for long-term disease management following surgery (KAS 6). For an adult who is a candidate for sinus surgery, the surgeon or their designee should obtain a computed tomography (CT) scan with a fine-cut protocol, if not already available, to examine the paranasal sinuses for surgical planning (KAS 7). The surgeon should not plan the extent of sinus surgery (eg, which specific sinuses to operate on) solely based on arbitrary criteria regarding a minimal level of mucosal thickening, sinus opacification, or outflow obstruction on a CT scan (KAS 8). The surgeon or their designee should educate an adult with chronic rhinosinusitis who is scheduled for sinus surgery regarding anticipated postoperative care, specifically pain control, debridement, medical management, activity restrictions, return to work, duration and frequency of follow-up visits, and the potential for recurrent disease or revision surgery (KAS 9). When the sinus involves polyps, osteitis, bony erosion, or fungal disease in an adult with chronic rhinosinusitis who is scheduled for sinus surgery, the surgeon should perform sinus surgery that includes full exposure of the sinus cavity (lumen) and removal of diseased tissue, not just balloon or manual ostial dilation, or refer the patient to a surgeon who can perform this extent of surgery (KAS 10). The surgeon or their designee should routinely follow up to assess and document outcomes of sinus surgery for chronic rhinosinusitis, between 3 and 12 months after the procedure, through history (symptom relief, quality of life, complications, adherence to therapy, need for rescue medications, and ongoing care) and nasal endoscopy (KAS 11). There were no recommendations that were considered options from the Guideline Development Group.
引用
- Shin JJ, Wilson M, McKenna M, et al. Executive Summary of the Clinical Practice Guideline on the Surgical Management of Chronic Rhinosinusitis. Otolaryngol Head Neck Surg. 2025. PMID: 40437675. doi:10.1002/ohn.1286
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。